Lineage-specific hematopoietic growth factors [11]

New England Journal of Medicine

Volumn 355, Issue 5, 2006, Pages 526-

  Ferretti, Gianluigi ^a   Papaldo, Paola ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CITRON; HUMAN; INCIDENCE; LETTER; MYELODYSPLASIA; PRIORITY JOURNAL; RISK FACTOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; LEUKEMIA; NOTE; SECOND CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA; NEOPLASMS, SECOND PRIMARY;

EID: 33746763832     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc061587     Document Type: Letter

References (5)

1. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006;354:2034-45.
2. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003;21:1195-204.
3. Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3066-71.
4. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9. [Erratum, J Clin Oncol 2003;21:2226.]
5. Di Cosimo S, Ferretti G, Papaldo P, et al. Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women? Ann Oncol 2005;16:1209-10.